CIBA-GEIGY's LAMPRENE (CLOFAZIMINE) "APPROVABLE"
Executive Summary
CIBA-GEIGY's LAMPRENE (CLOFAZIMINE) "APPROVABLE" status was made by FDA Oct. 31. Lamprene in 50 mg and 100 mg capsule form will be used to treat Hansen's disease (leprosy). The NDA for Lamprene, an orphan drug, was filed June 28, 1985. According to Ciba-Geigy, the firm already markets Lamprene in India and other third world countries. The Centers for Disease Control reports that the incidence of leprosy in the U.S. has increased steadily in the past 20 years. In 1965, there were 96 new Hansen's disease cases diagnosed, 162 new cases in 1975, 223 in 1980, and 290 new cases reported in 1984. The agency attributes the increased incidence largely to immigration of leprosy victims to the U.S.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth